Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5798197 | 0.83 | NOTUM (0.35) | KMO | |
| SCHEMBL29993075 | 0.73 | AHR (0.55) | KMOEGLN2FFAR1PTGS1PTGS2 | |
| SCHEMBL3934141 | 0.69 | PTGS2 (0.39) | KMOPTGS1PTGS2 | |
| SCHEMBL1275684 | 0.68 | PTGS2 (0.35) | KMOEGLN2PTGS1PTGS2ERCC5 | |
| SCHEMBL1275685 | 0.68 | AHR (0.38) | KMOEGLN2FFAR1PTGS1PTGS2 | |
| SCHEMBL4006606 | 0.67 | — | — | |
| SCHEMBL31067094 | 0.66 | AHR (0.46) | KMOEGLN2FFAR1PTGS1PTGS2 | |
| SCHEMBL533100 | 0.66 | AHR (0.41) | KMOEGLN2FFAR1PTGS1PTGS2 | |
| SCHEMBL30936103 | 0.65 | ESR2 (0.52) | KMOEGLN2FFAR1ERCC5FEN1 | |
| SCHEMBL1042848 | 0.65 | ESR2 (0.52) | KMOEGLN2FFAR1ERCC5FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183897-A9 | MUCIN GLYCANS AS ANTIFUNGAL AGENTS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20230321186-A1 | Mucin Glycans as Antifungal Agents | UNIVERSITÄT BASEL (CH) | 2023-10-12 | — | — | US | disclosed |
| WO-2023183897-A1 | MUCIN GLYCANS AS ANTIFUNGAL AGENTS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-2508888-A1 | Method for diagnosing a hepatic disease by sugar chain analysis | National University Corporation Hokkaido University (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-20100301203-A1 | METHOD OF DIAGNOSTIC HEPARIC DISEASE BY SUGAR CHAIN ANALYSIS | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2010-12-02 | — | — | US | disclosed |
| EP-2224235-A1 | METHOD OF DIAGNOSTIC HEPATIC DISEASE BY SUGAR CHAIN ANALYSIS | National University Corporation Hokkaido University (JP) | 2010-09-01 | — | — | EP | disclosed |
| EP-2216025-A2 | Use of acylaminoalkenylene-amide derivatives in irritable bowel syndrome and functional dyspepsia | Novartis AG (CH) | 2010-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321186-A1 | Mucin Glycans as Antifungal Agents | MUC1, FUT5, FUT8 | KMO 1489/4885EGLN2 4716/4885FFAR1 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.